Source comparison
Melanotan-1 Work for EPP Research History: Comparison of Clinical Trials
CUV029 (Leiden, 2009) Phase II, randomized, placebo-controlled n=93 EPP patients Change in pain-free sun exposure (minutes) Median increase: 7→50 minutes (p<0.001) Mild nausea (12%), implant site reaction (8%), no serious AEs First trial establishing clinical
This comparison does not assign a generated winner or score.
- CUV029 (Leiden, 2009)
- Phase II, randomized, placebo-controlled
- n=93 EPP patients
- Change in pain-free sun exposure (minutes)
- Median increase: 7→50 minutes (p<0.001)
- Mild nausea (12%), implant site reaction (8%), no serious AEs
- First trial establishing clinical efficacy. Set dosing standard still used in 2026
- CUV039 (multi-centre EU/US, 2015)
- Phase III, double-blind
- n=74 EPP patients
- Total hours with no pain across 180-day period
- 6-hour median increase vs placebo (69.4 vs 40.8 hours, p=0.04)
- Headache (18%), hyperpigmentation (100% reversible), 2 dropouts for nausea
- Pivotal trial for FDA approval. Demonstrated reproducible benefit in geographically diverse cohort
- Italian EPP Registry (Padua, 2019)
- Observational, real-world use
- n=48 EPP patients, 5-year follow-up
- Quality of life (DLQI scores)
- DLQI improved from 18.2→7.6 (clinically meaningful threshold >4-point change)
- Long-term hyperpigmentation concerns in 6 patients (resolved within 12 months post-discontinuation)
- Confirmed durability of benefit beyond controlled trial settings. Real-world adherence 91%
- Pediatric EPP Study (Zurich/Rotterdam, 2022)
- Open-label, age 6–17 cohort
- n=28 pediatric EPP patients
- Parent-reported outdoor activity tolerance
- 4.2-fold increase in outdoor play hours per week
- Growth velocity unchanged, sexual maturation unaffected, MC1R stimulation did not alter pubertal timing
- Extended indication to pediatric population. Critical for school-age functional impairment